| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sozinibercept | OPT-302; VGX-300 | Phase 3 Clinical | Orphan Europe Sarl | Neovascularization, Pathologic; Retinal Diseases; Diabetic macular oedema; Retinal Degeneration; Eye Diseases; Macular Degeneration | Details |
| EG-016 | EG-016; Ad-VEGF-A | Phase 2 Clinical | Ark Therapeutics Ltd | Peripheral Vascular Diseases | Details |
| EG-011 | EG-011; Ad-VEGF-D | Phase 2 Clinical | Ark Therapeutics Ltd | Angina Pectoris | Details |

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8



